PLX Protalix BioTherapeutics, Inc.
NYSE · SEC CIK 1006281 · EDGAR
- Bought, last 12 months
- $101.4K 1 purchases by 1 insiders
- Sold, last 12 months
- $314.16 1 sales by 1 insiders
- Filings on record
- 51 since 2022-02-28, latest 2026-09-09 17:00
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Bashan Dror | Pres AND CEO, Dir | $101.4K | — |
| Bar-Shalev Amos | Dir | — | $314.16 |
Transactions 24
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-23 | 2025-12-19 | PLX | Bashan Dror | Pres AND CEO, Dir | P - Purchase | $1.81 | +56.0K | 188.5K | +42% | +$101.4K | |
| 2025-11-19 | 2025-11-18 | PLX | Bar-Shalev Amos | Dir | S - Sale | $1.87 | -168 | 0 | -100% | -$314.16 | |
| DI | 2025-09-04 | 2025-09-03 | PLX | Bashan Dror | Pres AND CEO, Dir | A - Grant | — | +195.0K | 2.34M | +9% | — |
| DI | 2025-09-04 | 2025-09-03 | PLX | Forster Eliot | Dir | A - Grant | — | +7,500 | 7,500 | New | — |
| DI | 2025-09-04 | 2025-09-03 | PLX | Ben Zvi Shmuel | Dir | A - Grant | — | +7,500 | 7,500 | New | — |
| DI | 2025-09-04 | 2025-09-03 | PLX | Melincoff Gwen A | Dir | A - Grant | — | +7,500 | 7,500 | New | — |
| DI | 2025-09-04 | 2025-09-03 | PLX | Schwartz Aharon | Dir | A - Grant | — | +7,500 | 7,500 | New | — |
| DI | 2025-09-04 | 2025-09-03 | PLX | Bar-Shalev Amos | Dir | A - Grant | — | +7,500 | 7,500 | New | — |
| DI | 2025-09-04 | 2025-09-03 | PLX | Naos Yaron | SVP, Ops | A - Grant | — | +25.0K | 225.8K | +12% | — |
| DI | 2025-09-04 | 2025-09-03 | PLX | Elze Christian | Dir | A - Grant | — | +7,500 | 7,500 | New | — |
| DI | 2025-09-04 | 2025-09-03 | PLX | Boudes Pol F | Dir | A - Grant | — | +7,500 | 7,500 | New | — |
| 2025-08-12 | 2025-06-10 | PLX | Schwartz Aharon | Dir | P - Purchase | $1.60 | +129.0K | 303.0K | +74% | +$206.4K | |
| AI | 2024-11-05 | 2024-09-23 | PLX | Rubin Eyal | SVP, CFO | A - Grant | — | +90.9K | 660.9K | +16% | — |
| I | 2024-09-24 | 2024-09-23 | PLX | Rubin Eyal | SVP, CFO | A - Grant | — | +99.0K | 669.0K | +17% | — |
| I | 2024-04-03 | 2024-04-01 | PLX | Bashan Dror | Pres AND CEO, Dir | A - Grant | — | +264.0K | 2.15M | +14% | — |
| M | 2023-10-20 | 2023-10-19 | PLX | Bashan Dror | Pres AND CEO, Dir | P - Purchase | $1.40 | +64.5K | 116.4K | +124% | +$90.5K |
| I | 2023-08-17 | 2023-08-15 | PLX | Naos Yaron | SVP, Ops | A - Grant | — | +187.3K | 200.8K | +1,391% | — |
| DI | 2023-08-17 | 2023-08-15 | PLX | Hayon Yael | VP, Research, Development | A - Grant | — | +35.1K | 35.1K | New | — |
| I | 2023-08-17 | 2023-08-15 | PLX | Bashan Dror | Pres, CEO, Dir | A - Grant | — | +800.0K | 1.89M | +74% | — |
| I | 2023-08-17 | 2023-08-15 | PLX | Rubin Eyal | SVP, CFO | A - Grant | — | +201.9K | 570.0K | +55% | — |
| 2023-01-05 | 2023-01-03 | PLX | Schwartz Aharon | Dir | P - Purchase | $1.42 | +110.0K | 174.0K | +172% | +$156.2K | |
| 2022-04-13 | 2022-04-11 | PLX | Bashan Dror | Pres, CEO, Dir | P - Purchase | $1.50 | +68.0K | 68.0K | New | +$102.0K | |
| I | 2022-02-28 | 2022-02-25 | PLX | Bashan Dror | Pres, CEO, Dir | A - Grant | — | +637.5K | 1.09M | +142% | — |
| I | 2022-02-28 | 2022-02-25 | PLX | Rubin Eyal | SVP, CFO | A - Grant | — | +122.0K | 368.1K | +50% | — |
Purchase Sale Sale after option exercise All abbreviations